益佰制药

600594 SSE 证监会行业分类 C27医药制造业

Key Metrics

Market Cap

2.9B ($423.3M)

P/E Ratio

N/A

P/B Ratio

N/A

Revenue

2.2B

Net Income

-335.0M

Gross Margin

N/A

Op. Margin

-14.4%

Net Margin

-15.4%

ROE

-12.9%

ROA

-8.2%

D/E

0.57

Dividend Yield

N/A

EPS

-0.40

Current Ratio

1.84

Price History

Company Info

Industry	C27医药制造业
Market Segment	Main Board
Currency	CNY
Fiscal Year	2024

Business Overview

Full Financials Advanced Charts Filings

Peers

工商银行

601398

2.7T

P/E: 7.6

建设银行

601939

2.5T

P/E: 7.2

农业银行

601288

2.4T

P/E: 8.7

中国海油

600938

2.0T

P/E: 16.2

宁德时代

300750

1.9T

P/E: 25.6

贵州茅台

600519

1.8T

P/E: 20.1

中国银行

601988

1.8T

P/E: 7.3

中国人寿

601628

1.2T

P/E: 6.9

Financial Statements

Loading financials...

Open Advanced Charts

Full charting with technical indicators, candlestick, and more.

About 益佰制药

Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatic bone, digestive system, pediatric, anti-infection, anti-inflammatory, analgesic, cancer, orthopedics, digestion, andrology, and urology. The company also engages in investment in the cultivation and breeding projects of medicinal materials; and agricultural products sale, as well as provides market information consulting services for medicinal materials. In addition, it is involved in the research and development, and information consulting services for health food. The company was founded in 1995 and is based in Guiyang, China.

Ticker	600594
Exchange	SSE
Sector	证监会行业分类
Industry	C27医药制造业